spring-dermatology-skin-care-2018-tracks

11 / 35

Page 27
Notes:
alliedacademies
Journal of Dermatology Research and Skin Care | Volume 2
May 14-15, 2018 | Montreal, Canada
Spring Dermatology &
Skin Care Expo Conference
Currently, onlyfinasteride1mg formalepatients andminoxidil
2 and 5% solution and 5% foam are FDA-approved for the
treatment of male and female pattern hair loss. Low-level laser
light therapy is FDA-cleared for the treatment of androgenetic
alopecia. In women with hyperandrogenism, spironolactone,
finasteride and ciproterone acetate appear useful. Finasteride
is a competitive inhibitor of type II 5-α-reductase, and
acts by decreasing the conversion of testosterone to
dihydrotestosterone. Minoxidil increases duration of anagen
and enlargesminiaturized follicles. It is also a potassiumchannel
opener and vasodilatator. Topical latanoprost 0.1%, topical
melatonin, a formulation containing follistatin, keratinocyte
growth factor (KGF), and vascular endothelial growth factor
(VEGF), plasma rich in growth factors and adipose-derived stem
cell‒conditioned medium could be useful for stimulating hair
follicle activity and treating hair loss. Serenoa repens extract has
been shown to inhibit both types of 5-α reductase. Treatment
should be used for 12 months before making a decision about
efficacy. In women on hormone replacement therapy or oral
contraceptive pill, the dose and type should be stabilized. DHEA
or testosterone should be avoided. Tinted powders, lotions, and
hair sprays, wigs, hair pieces, and hair extensions can provide
cosmetic relief to patients.
Speaker Biography
Renata Indelicato Zac is a Brazilian Dermatologist and has her expertise in Clinical and
Cosmetic Dermatology and is pursuing her Master’s degree in Health Science. She is
the Director of Clinica Attento, Belo Horizonte, MG, Brazil, and Mentor in dermatology
training at Minas Gerais’ Military Hospital.
e:
Renata Indelicato Zac
Minas Gerais’ Military Hospital, Brazil
Exploring the clinical treatments for Alopecia